Prescriber Criteria Form

Leuprolide inj 2024 PA Fax 4629-A v3 010124.docx Leuprolide acetate injection solution Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at 1-855-633-7673.

Please contact CVS Caremark at 1-866-785-5714 with questions regarding the prior authorization process.

When conditions are met, we will authorize the coverage of Leuprolide acetate injection solution.

Drug Name:

Leuprolide acetate injection solution	1		
Patient Name:			
Patient ID:			
Patient DOB:	Patient Phone:		
Prescriber Name:	·		
Prescriber Address:			
City:	State:	Zip:	
Prescriber Phone:	Prescriber Fax:		
Diagnosis:	ICD Code(s):		

Plea	Please circle the appropriate answer for each question.		
1	Does the patient have a diagnosis of prostate cancer?	Yes	No
	[If yes, then no further questions.]		
2	Is the requested drug being prescribed for the treatment of recurrent androgen receptor	Yes	No
	positive salivary gland tumor?		
	[If yes, then no further questions.]		
3	Is the requested drug being prescribed for a child with growth failure and advancing	Yes	No
	puberty?		
	[If no, then skip to question 5.]		
4	Will the requested drug be used in combination with growth hormone?	Yes	No
	[No further questions.]		
5	Does the patient have a diagnosis of central precocious puberty (CPP)?	Yes	No
	[If no, then no further questions.]		
6	Is the patient currently receiving the prescribed medication?	Yes	No
	[If yes, then skip to question 12.]		
7	Has the diagnosis of central precocious puberty (CPP) been confirmed by a pubertal	Yes	No
	response to a gonadotropin releasing hormone (GnRH) agonist test OR a pubertal level		

Presci	riber (or Authorized) Signature: Date:		
	ning this form, I attest that the information provided is accurate and true as of this date and the entation supporting this information is available for review if requested by the health plan.	at the	
Comm			
12	Is the patient less than 12 years of age if female or less than 13 years of age if male?	Yes	No
11	Did the onset of secondary sexual characteristics occur prior to nine years of age? [If no, then no further questions.]	Yes	No
	[If no, then no further questions.]		
10	Did the onset of secondary sexual characteristics occur prior to eight years of age? [If yes, then skip to question 12.]	Yes	No
9	Is the patient female? [If no, then skip to question 11.]	Yes	No
	central precocious puberty (CPP)? [If no, then no further questions.]		
8	of a third generation luteinizing hormone (LH) assay? [If no, then no further questions.] Does the assessment of bone age versus chronological age support the diagnosis of	Yes	No